Ethylamine compound with activity of resisting non-small cell lung cancer

By providing an ethylamine compound, the treatment difficulties of non-small cell lung cancer, especially patients with CLIP1-LTK fusion gene positive in the art were solved, and the significant performance of Ba/F3-CLIP1-LTK cells and LTK enzymes was demonstrated. Inhibiting activity has achieved effective targeted treatment for non-small cell lung cancer.

CN119015276APending Publication Date: 2024-11-26WEIFANG UNIV OF SCI & TECH
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411255266.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art is difficult to effectively target the treatment of non-small cell lung cancer, especially patients with positive CLIP1-LTK fusion gene, and lack selective small molecule inhibitors for LTK.

Method used

It provides an ethylamine compound with anti-non-small cell lung cancer activity, and its structure is: in which the R group is selected from the alkane groups of H, C1 to C4, and is used for the preparation of anti-non-small cell lung cancer drugs or for experimental purposes. LTK inhibitor, demonstrated good inhibitory activity on Ba/F3-CLIP1-LTK cells and LTK enzymes.

Benefits of technology

The ethylamine compound showed significant inhibitory activity on Ba/F3-CLIP1-LTK cells and LTK enzymes at different concentrations, with semi-inhibitory concentrations of 8.23μM/L and 2.61μM/L, respectively, showing potential treatment and research value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015276A_ABST
    Figure CN119015276A_ABST
Patent Text Reader

Abstract

The invention discloses an application of an ethylamine compound or an acceptable derivative thereof in preparation of an anti-non-small cell lung cancer drug. When the ethylamine compounds with different concentrations provided by the invention are subjected to inhibitory activity experiments on Ba / F3-CLIP1-LTK cells and LTK enzyme, the compounds show good inhibitory activity, the semi-inhibitory concentrations IC50 of the compounds are 8.23 mu M / L and 2.61 mu M / L respectively, and the compounds have good application prospects in the aspect of resisting non-small cell type lung cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the pharmaceutical field, and in particular to an ethylamine compound having anti-non-small cell lung cancer activity. Background Art

[0002] Lung cancer is mainly divided into two categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), of which non-small cell lung cancer accounts for as much as 85%. Stratified targeted therapy for carcinogenic factors has significantly improved the treatment effect of lung cancer patients, especially the survival rate of lung cancer patients carrying specific carcinogenic factors has been greatly improved. Gene fusion-activated protein kinases are an important class of oncogenes closely related to hematopoietic malignancies and solid tumors. They are usually generated by chromosomal translocations or other rearrangement events, and the protein products they encode are often ideal targets for the development of anticancer drugs.

[0003] Current studies have shown that protein fusion between CLIP1 protein and LTK protein is the key to cell carcinogenic transformation. Whole transcriptome sequencing analysis of non-small cell lung cancer samples with unknown driver genes showed that specific transcripts encoding CLIP1-LTK protein were found in tumor samples of these patients. Further transformation experiments showed that CLIP1-LTK fusion protein, depending on its own kinase activity, exhibited the ability to cause carcinogenic transformation in NIH3T3 fibroblasts and Ba / F3 pro-B lymphocytes. Moreover, in tumor samples positive for the CLIP1-LTK fusion gene, other known oncogenic driver genes were negative, indicating that the CLIP1-LTK fusion gene is mutually exclusive with other known driver genes, and therefore is expected to become a potential target for the treatment of CLIP1-LTK fusion-positive cancer patients.

[0004] As a member of the microtubule end tracer protein family, CLIP1 binds to microtubules through its N-terminal CAP-Gly domain and participates in a variety of microtubule-related intracellular activities, such as the connection between centromeres and microtubules during mitosis, directional cell migration, etc. In addition, CLIP1 can also interact with other microtubule-binding proteins, such as EB1 protein and CLASP family proteins that are also located at the plus end of microtubules, so as to more accurately locate at the plus end of microtubules.

[0005] LTK is a member of the receptor tyrosine kinase family, and its protein sequence includes an extracellular region, a transmembrane region, and an intracellular tyrosine kinase region. The intracellular region is composed of a juxtamembrane region, a protein kinase domain, and a carboxyl terminus, wherein the protein kinase domain contains a smaller N-terminal lobe and a larger C-terminal lobe, with the ATP binding site located between the two. The protein sequences of LTK and ALK are highly homologous, especially the identity of the kinase domain sequence can reach 79%, but the extracellular domain structure of LTK is relatively small and contains only two MAM domains. At present, there are few studies on the biological function of wild-type LTK. The only studies suggest that it may play a role in animal autoimmunity and neural development. There are no reports of selective small molecule inhibitors for LTK, and the protein structure of LTK has not yet been resolved.

[0006] It is a compound in the commercial compound library, with the IUPAC name [2-(1H-indol-3-yl)ethyl]{3-methoxy-4-[(1-phenyl-1H-tetrazol-5-yl)oxy]benzyl}amine, and its compound numbers include STK511799, AKOS001481219, CCG-197949, and AN-465 / 43411044. No studies have shown that it has any special activity. Summary of the invention

[0007] The object of the present invention is to overcome at least one deficiency of the prior art and provide an ethylamine compound having anti-non-small cell lung cancer activity.

[0008] The technical solution adopted by the present invention is: In the first aspect, the present invention provides an ethylamine compound or an acceptable derivative thereof for use in the preparation of an anti-non-small cell lung cancer drug, wherein the ethylamine compound has a structure as shown in the following formula: ; In the formula, the R group is selected from H and C1-C4 alkane groups.

[0009] In some examples, the R group is methyl.

[0010] In some examples, the derivative of the ethylamine compound is a pharmaceutically acceptable salt thereof.

[0011] In some examples, the non-small cell lung cancer disease includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

[0012] In some examples, the non-small cell lung cancer is CLIP1-LTK fusion gene positive non-small cell lung cancer.

[0013] In some examples, the drug further comprises a pharmaceutically acceptable excipient, wherein the excipient comprises at least one of a solvent, a filler, a lubricant, a disintegrant, a buffer, a solubilizing agent, an antioxidant, an antibacterial agent, an emulsifier, a binder or a suspending agent.

[0014] In some examples, the drug is in the form of intravenous injection, suppository, gel, foam, enteric solvent, decoction, mixture, syrup, granule, pill, capsule, gel or nanoformulation.

[0015] In a second aspect, the present invention provides an ethylamine compound or an acceptable derivative thereof for use in preparing an experimental LTK inhibitor, wherein the ethylamine compound has a structure shown in the following formula: ; In the formula, the R group is selected from H, C1-C4 alkane group; The use does not include the treatment of disease.

[0016] In some examples, the R group is methyl.

[0017] In some examples, the derivative of the ethylamine compound is a pharmaceutically acceptable salt thereof.

[0018] The beneficial effects of the present invention are: When the ethylamine compounds of different concentrations provided by the present invention were subjected to the inhibitory activity experiments on Ba / F3-CLIP1-LTK cells and LTK enzyme, the compounds all showed good inhibitory activity, and their half inhibitory concentration IC 50 8.23μM / L and 2.61μM / L respectively. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is the inhibition curve of the ethylamine compounds provided by the present invention on Ba / F3-CLIP1-LTK.

[0020] Figure 2 This is the inhibition curve of the ethylamine compounds provided by the present invention on LTK. DETAILED DESCRIPTION

[0021] The following disclosure provides many different embodiments or examples for implementing different solutions of the present invention.

[0022] Anti-cell proliferation activity assay Experimental principle: The anti-cell proliferation effect of the compound is determined using the MTT (thiazolyl blue) experiment. MTT can be reduced to water-insoluble blue-purple crystalline formazan by succinate dehydrogenase in the cell mitochondria and deposited in living cells, while dead cells do not have this function. Dimethyl sulfoxide can dissolve the formazan in the cells, and its light absorption value can be measured at a wavelength of 570nm by an enzyme-linked immunosorbent assay, which can indirectly reflect the number of living cells.

[0023] Experimental method: First, 8 groups of compound solutions with different concentrations (0.58 nmol / l, 2.91 nmol / l, 14.53 nmol / l, 32 nmol / l, 363.22 nmol / l, 1816.12 nmol / l, 9080.59 nmol / l and 45402.95 nmol / l) were prepared.

[0024] Ba / F3-CLIP1-LTK cell suspension was prepared using RPMI-1640 medium without IL-3, and 90 μL of the cell suspension was seeded into each well of a 96-well plate.

[0025] Subsequently, the 96-well plate was placed in a cell culture incubator for 2 hours, after which the prepared ethylamine compounds or dimethyl sulfoxide were added to each well. After 72 hours of culture, 10 μL of MTT solution was added to each well and incubated for another 4 hours. After that, 100 μL of SDS-HCl-PBS triple buffer solution was added to dissolve the formed formazan crystals. Finally, the absorbance value of each well at 570 nm was monitored using an ELISA reader, and the data was fitted into a concentration-response curve with a variable slope, from which the IC 50 value.

[0026] Experimental results: The anti-proliferation experiment of Ba / F3-CLIP1-LTK cells was carried out using different concentrations of ethylamine compounds. It was found that the compound had a good inhibitory activity on Ba / F3-CLIP1-LTK cells, and its half inhibitory concentration IC 50 8.23 μM / L( Figure 1 ).

[0027] LTK enzyme inhibition activity assay Experimental principle: The measurement of the inhibitory activity of ethylamine compounds on LTK uses the LanthaScreenTM kinase assay based on TR-FRET technology to determine the kinase inhibitory activity of the compounds.

[0028] Experimental method: All experiments were performed in 384-well plates. Before the experiment, 8 groups of compound solutions with different concentrations (0.58 nmol / l, 2.91 nmol / l, 14.53 nmol / l, 32 nmol / l, 363.22 nmol / l, 1816.12 nmol / l, 9080.59 nmol / l and 45402.95 nmol / l) were prepared.

[0029] Then, 4 sets of recombinant human LTK protein and 2 sets of substrate / ATP mixture were prepared in a buffer solution containing 50 mM HEPES (pH 7.5), 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1mM EGTA and 2 mM DTT4. The kinase reaction system finally contained 10 uL of the mixture, including 5 μL of 1× substrate / ATP mixture (0.2 μM substrate and 5 μM ATP), 2.5 μL of LTK protein (5 ng / ml) and 2.5 μL of 1× test compound at the desired concentration.

[0030] The assay plate was shaken on a shaker for 30 seconds to ensure that the reactants were thoroughly mixed. The kinase reaction was then allowed to proceed for 1 hour at room temperature (20 – 25°C). Afterwards, 10 μL of the pre-prepared stop solution (containing 20 mM EDTA and 4 nM Tb-labeled antibody) was added to stop the kinase reaction and trigger antibody binding, and the assay plate was incubated for another 1 hour at room temperature.

[0031] Subsequently, the emission signals of fluorescein and terbium (excitation wavelength was 340 nm; emission wavelengths were 520 nm and 495 nm, respectively) were measured using a fluorescence plate reader (BioTek SynergyTM 4) with a delay time of 100 μs and an integration time of 200 μs.

[0032] Finally, the inhibitory activity was calculated based on the TR-FRET emission ratio (i.e., the ratio of the emission intensity of fluorescein to the emission intensity of terbium) and plotted against the concentration of the inhibitor. The data were fitted to a concentration-response curve with a variable slope, from which the IC 50 value.

[0033] Experimental results: The enzyme inhibition activity of LTK was tested by using ethylamine compounds at different concentrations. It was found that ethylamine compounds had good inhibitory activity, and their half inhibitory concentration IC 50 2.61μM / L( Figure 2 ).

[0034] The above is a further detailed description of the present invention, which should not be regarded as a limitation on the specific implementation of the present invention. For ordinary technicians in the technical field to which the present invention belongs, simple deduction or replacement without departing from the concept of the present invention is within the protection scope of the present invention.

Claims

1. Use of ethylamine compounds or acceptable derivatives thereof in the preparation of anti-non-small cell lung cancer drugs, characterized in that: The ethylamine compound has a structure as shown in the following formula: ; In the formula, the R group is selected from H and C1-C4 alkane groups.

2. The use according to claim 1, characterized in that: The R group is methyl.

3. The use according to claim 1, characterized in that: The derivatives of the ethylamine compounds are pharmaceutically acceptable salts thereof.

4. The use according to claim 1, characterized in that: The non-small cell lung cancer disease includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma.

5. The use according to claim 1 or 4, characterized in that: The non-small cell lung cancer is CLIP1-LTK fusion gene positive non-small cell lung cancer.

6. The use according to claim 1, characterized in that: The drug also includes pharmaceutically acceptable excipients, which include at least one of solvents, fillers, lubricants, disintegrants, buffers, solubilizers, antioxidants, antibacterial agents, emulsifiers, binders or suspending agents.

7. The use according to claim 1, characterized in that: The dosage form of the medicine is intravenous injection, suppository, gel, foam, enteric solvent, decoction, mixture, syrup, granule, pill, capsule, gel or nano preparation.

8. Use of ethylamine compounds or acceptable derivatives thereof in the preparation of experimental LTK inhibitors, characterized in that: The ethylamine compound has a structure as shown in the following formula: ; In the formula, the R group is selected from H, C1-C4 alkane group; The use does not include the treatment of disease.

9. The use according to claim 8, characterized in that: The R group is methyl.

10. The use according to claim 9, characterized in that: The derivatives of the ethylamine compounds are pharmaceutically acceptable salts thereof.

Citation Information

Cited By

  • 5-phenoxy tetrazole compound, reagent thereof, preparation method of 5-phenoxy tetrazole compound and application of 5-phenoxy tetrazole compound in preparation of antitumor drugs

    CN120441500A

  • A 5-phenoxytetrazole compound, combination therapy, and its application in antitumor treatment

    GB2704785A